Patents by Inventor Sing-Yuen Sit

Sing-Yuen Sit has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20040106559
    Abstract: Hepatitis C virus inhibitors are disclosed having the general formula: 1
    Type: Application
    Filed: May 20, 2003
    Publication date: June 3, 2004
    Inventors: Xiangdong Alan Wang, Li-Qiang Sun, Sing-Yuen Sit, Ny Sin, Paul Michael Scola, Piyasena Hewawasam, Andrew Charles Good, Yan Chen, Jeffrey Allen Campbell
  • Publication number: 20040063741
    Abstract: The present invention relates to the preparation of the optical isomer (R)-(+)-8,9-dihydroxy-2,3,7,11b-tetrahydro-1H-napth[1,2,3-de]isoquinoline. This invention also relates to the use of pharmaceutical compositions comprising (R)-(+)-8,9-dihydroxy-2,3,7,11b-tetrahydro-1H-napth[1,2,3-de]isoquinoline for use for the treatment of movement disorders.
    Type: Application
    Filed: April 2, 2003
    Publication date: April 1, 2004
    Inventor: Sing-Yuen Sit
  • Patent number: 6645975
    Abstract: The present invention relates to a novel process for the preparation of compounds of the formula wherein R1, R2, R4, R5, R6 and A are as defined herein, and to certain derivations of Formula IX which are useful for the treatment of movement disorders.
    Type: Grant
    Filed: January 27, 2003
    Date of Patent: November 11, 2003
    Assignee: Purdue Research Foundation
    Inventors: Sing-Yuen Sit, Swanee E. Jacutin-Porte
  • Publication number: 20030195226
    Abstract: The present invention relates to novel oxime carbamyl derivatives and pharmaceutical compositions comprising said derivatives which inhibit fatty acid amide hydrolase. These pharmaceutical compositions are useful for the treatment of conditions which can be effected by inhibiting fatty acid amide hydrolase including, but not limited to, neuropathic pain, emesis, anxiety, altering feeding behaviors, movement disorders, glaucoma, brain injury, and cardiovascular disease.
    Type: Application
    Filed: February 4, 2003
    Publication date: October 16, 2003
    Inventors: Sing-Yuen Sit, Kai Xie, Hongfeng Deng
  • Patent number: 6562846
    Abstract: The present invention relates to bisarylimidazolyl derivatives and pharmaceutical compositions comprising said compounds inhibiting fatty acid amide hydrolase and useful for the treatment of pain, particularly neuropathic pain, psychomotor disorder, hypertension, cardiovascular disease, eating disorder, nausea, AIDS-related complex, glaucoma, inflammation, psoriasis or multiple sclerosis, and other conditions the treatment of which can be effected by inhibiting fatty acid amide hydrolase.
    Type: Grant
    Filed: April 23, 2002
    Date of Patent: May 13, 2003
    Assignee: Bristol-Myers Squibb Company
    Inventors: Sing-Yuen Sit, Kai Xie
  • Publication number: 20020188009
    Abstract: The present invention relates to bisarylimidazolyl derivatives and pharmaceutical compositions comprising said compounds inhibiting fatty acid amide hydrolase and useful for the treatment of pain, particularly neuropathic pain, psychomotor disorder, hypertension, cardiovascular disease, eating disorder, nausea, AIDS-related complex, glaucoma, inflammation, psoriasis or multiple sclerosis, and other conditions the treatment of which can be effected by inhibiting fatty acid amide hydrolase.
    Type: Application
    Filed: April 23, 2002
    Publication date: December 12, 2002
    Inventors: Sing-Yuen Sit, Kai Xie
  • Patent number: 6479482
    Abstract: A series of non-peptidergic antagonists of NPY have been synthesized and are comprises of amino and piperazine derivatives of 4-phenyl-1,4-dihydropyridines of Formula 1. where X is CH or N As antagonists of NPY-induced behavior, these compounds are expected to act as effective anorexiant agents in promoting weight loss and treating eating disorders.
    Type: Grant
    Filed: May 10, 2001
    Date of Patent: November 12, 2002
    Assignee: Bristol-Myers Squibb Company
    Inventors: Graham S. Poindexter, Marc Bruce, Sing-Yuen Sit, Scott W. Martin
  • Patent number: 6444675
    Abstract: A series of non-peptidergic antagonists of NPY have been synthesized and are comprised of 4-alkyl and cycloalkyl derivatives of dihydropyridines of Formula I. As antagonists of NPY-induced behavior, these compounds are expected to act as effective anorexiant agents in promoting weight loss and treating eating disorders.
    Type: Grant
    Filed: April 24, 2001
    Date of Patent: September 3, 2002
    Assignee: Bristol-Myers Squibb Company
    Inventor: Sing-Yuen Sit
  • Patent number: 6432960
    Abstract: A series of antagonists of NPY have been synthesized and are comprised of squarate derivatives of 4-phenyl-1,4-dihydropyridines of Formula (I). As antagonists of NPY-induced behavior, these compounds are expected to act as effective anorexiant agents in promoting weight loss and treating eating disorders.
    Type: Grant
    Filed: April 24, 2001
    Date of Patent: August 13, 2002
    Assignee: Bristol-Myers Squibb Company
    Inventors: Sing-Yuen Sit, Graham S. Poindexter
  • Patent number: 6391881
    Abstract: A series of antagonists of NPY have been synthesized and are comprised of thiourea linked piperazine and piperidine derivatives of 4-phenyl-1,4-dihydropyridines of Formula 1. where Z is NR7R8 or and X is CH or N. As antagonists of NPY-induced behavior, these compounds are expected to act as effective anorexiant agents in promoting weight loss and treating eating disorders.
    Type: Grant
    Filed: April 24, 2001
    Date of Patent: May 21, 2002
    Assignee: Bristol-Myers Squibb Company
    Inventor: Sing-Yuen Sit
  • Publication number: 20020019384
    Abstract: A series of non-peptidergic antagonists of NPY have been synthesized and are comprises of amino and piperazine derivatives of 4-phenyl-1,4-dihydropyridines of Formula 1.
    Type: Application
    Filed: May 10, 2001
    Publication date: February 14, 2002
    Inventors: Graham S. Poindexter, Marc Bruce, Sing-Yuen Sit, Scott W. Martin
  • Publication number: 20010049370
    Abstract: A series of non-peptidergic antagonists of NPY have been synthesized and are comprised of 4-alkyl and cycloalkyl derivatives of dihydropyridines of Formula I.
    Type: Application
    Filed: April 24, 2001
    Publication date: December 6, 2001
    Inventor: Sing-Yuen Sit
  • Publication number: 20010047002
    Abstract: A series of antagonists of NPY have been synthesized and are comprised of squarate derivatives of 4-phenyl-1,4-dihydropyridines of Formula (I).
    Type: Application
    Filed: April 24, 2001
    Publication date: November 29, 2001
    Inventors: Sing-Yuen Sit, Graham S. Poindexter
  • Publication number: 20010047003
    Abstract: A series of antagonists of NPY have been synthesized and are comprised of thiourea linked piperazine and piperidine derivatives of 4-phenyl-1,4-dihydropyridines of Formula 1.
    Type: Application
    Filed: April 24, 2001
    Publication date: November 29, 2001
    Inventor: Sing-Yuen Sit
  • Patent number: 6177429
    Abstract: The present invention provides a series of non-peptidergic antagonists of NPY comprising piperidine and piperazine derivatives of 4-phenyl-1,4-dihydropyrazines of the Formula I wherein R, R1 X, Y and Z are defined herein. As antagonists of NPY-induced feeding behavior, these compounds are expected to act as effective anorexiant agents in promoting weight loss and treating eating disorders.
    Type: Grant
    Filed: June 6, 2000
    Date of Patent: January 23, 2001
    Assignee: Bristol-Myers Squibb Company
    Inventors: Sing-Yuen Sit, Yazhong Huang
  • Patent number: 6001836
    Abstract: A series of non-peptidergic antagonists of NPY have been synthesized and are comprised of cyanoguanidine derivatives of 4-phenyl-1,4-dihydropyridines of Formula (I). ##STR1## As antagonists of NPY-induced feeding behavior, these compounds are expected to act as effective anorexiant agents in promoting weight loss and treating eating disorders.
    Type: Grant
    Filed: May 26, 1998
    Date of Patent: December 14, 1999
    Assignee: Bristol-Myers Squibb Company
    Inventors: Graham S. Poindexter, R. Thomas Swann, Marc A. Bruce, Mendi A. Morton, Yazhong Huang, Sing-Yuen Sit, James Guy Breitenbucher
  • Patent number: 5922735
    Abstract: There is provided novel substituted 4-aryl-3-hydroxyquinolin-2-one derivatives of the formula ##STR1## wherein R is hydrogen or methyl;R.sup.1, R.sup.2, R.sup.3 and R.sup.4 each are independently hydrogen, bromo, chloro or trifluoromethyl, and when R.sup.1, R.sup.3 and R.sup.4 are hydrogen, R.sup.2 is nitro;R.sup.5 is hydrogen or methyl; andR.sup.6 is bromo or chloro;or a nontoxic pharmaceutically acceptable salt thereof, which are openers of the large-conductance calcium-activated potassium channels and are useful in the treatment of disorders which are responsive to the opening of the potassium channels.
    Type: Grant
    Filed: October 5, 1998
    Date of Patent: July 13, 1999
    Assignee: Bristol-Myers Squibb COmpany
    Inventors: Sing-Yuen Sit, Nicholas A. Meanwell
  • Patent number: 5892045
    Abstract: There is provided novel substituted 4-aryl-3-hydroxyquinolin-2-one derivatives of the formula ##STR1## wherein R is hydrogen or methyl;R.sup.1, R.sup.2, R.sup.3 and R.sup.4 each are independently hydrogen, bromo, chloro or trifluoromethyl, and when R.sup.1, R.sup.3 and R.sup.4 are hydrogen, R.sup.2 is nitro;R.sup.5 is hydrogen or methyl; andR.sup.6 is bromo or chloro;or a nontoxic pharmaceutically acceptable salt thereof, which are openers of the large-conductance calcium-activated potassium channels and are useful in the treatment of disorders which are responsive to the opening of the potassium channels.
    Type: Grant
    Filed: November 18, 1997
    Date of Patent: April 6, 1999
    Assignee: Bristol-Myers Squibb Company
    Inventors: Sing-Yuen Sit, Nicholas A. Meanwell
  • Patent number: 5321046
    Abstract: Disclosed herein are novel unsymmetrical dithiol ketals which are useful in the treatment or prevention of hypercholesterolemia, hyperlipoproteinemia, and atherosclerosis.
    Type: Grant
    Filed: October 27, 1992
    Date of Patent: June 14, 1994
    Assignee: Bristol-Myers Squibb Company
    Inventors: Sing-Yuen Sit, John J. Wright, Jeff A. Field
  • Patent number: 5110940
    Abstract: Compounds of the formula ##STR1## wherein R.sup.1 and R.sup.4 each are independently hydrogen, halogen, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, or trifluoromethyl;R.sup.2,R.sub.3,R.sup.5 and R.sup.6 each are independently hydrogen, halogen C.sub.1-4 alkyl or C.sub.1-4 alkoxy;tet is ##STR2## n is an integer of from 0 to 2, inclusive; A is ##STR3## R.sup.7 is hydrogen, C.sub.1-4 alkyl, C.sub.1-4 alkoxy(lower) alkyl or (2-methoxyethoxy)methyl;X is --OH or .dbd.O; andR.sup.8 is hydrogen, a hydrolyzable ester group or a cation to form a non-toxic pharmaceutically acceptable salt,are novel antihypercholesterolemic agents which inhibit cholesterol biosynthesis. Intermediates and processes for their preparation are disclosed.
    Type: Grant
    Filed: May 6, 1991
    Date of Patent: May 5, 1992
    Assignee: Bristol-Myers Company
    Inventors: Sing-Yuen Sit, John J. Wright